Related Experiment Videos

A prospective analysis of cholestasis in infants supported with extracorporeal membrane oxygenation

B Shneider1, J Cronin, L Van Marter

  • 1Department of Medicine, Children's Hospital, Boston, Massachusetts.

Insights

Infant cholestasis during extracorporeal membrane oxygenation is linked to hemolysis and di-(2-ethylhexyl) phthalate exposure. These factors may inhibit bilirubin excretion, leading to direct hyperbilirubinemia.

Area of Science:

  • Neonatalogy
  • Pediatric Gastroenterology
  • Critical Care Medicine

Background:

  • Cholestasis is a common complication in infants requiring extracorporeal membrane oxygenation (ECMO).
  • The exact causes of ECMO-associated cholestasis are not fully understood.
  • Potential contributing factors include hemolysis and exposure to plasticizers like di-(2-ethylhexyl) phthalate.

Purpose of the Study:

  • To prospectively investigate the association between hemolysis and di-(2-ethylhexyl) phthalate exposure with cholestasis in infants on ECMO.
  • To identify key factors contributing to the development and severity of cholestasis during ECMO support.

Main Methods:

  • Prospective study design.
  • Measurement of di-(2-ethylhexyl) phthalate levels.
  • Quantification of hemolysis via maximum free hemoglobin levels.
  • Assessment of cholestasis and other clinical/laboratory parameters.

Main Results:

  • Both di-(2-ethylhexyl) phthalate levels and hemolysis (maximum free hemoglobin) were significantly associated with the degree of cholestasis (p < 0.025).
  • Other investigated clinical and laboratory factors did not show a significant relationship with cholestasis severity.
  • Findings suggest a link between ECMO-related hemolysis, phthalate exposure, and cholestasis development.

Conclusions:

  • Hemolysis during ECMO may generate a substantial bilirubin load.
  • Di-(2-ethylhexyl) phthalate exposure might impair bilirubin excretion, potentially via mechanisms similar to inspissated bile syndrome.
  • This leads to direct hyperbilirubinemia with minimal hepatocellular or canalicular injury in ECMO-supported infants.

Related Concept Videos